This is signal about capital allocators' appetite for model training infrastructure. Training data and optimization are becoming venture-fundable categories at scale. For builders: if you're generating synthetic data or working on training efficiency, this is validation. For investors: the model training layer is hot, but AfterQuery's actual product and defensibility matter more than the valuation headline.
Pande's argument that open, shared datasets beat walled-off proprietary ones is a direct challenge to how most biotech AI startups currently operate, hoarding data as a moat. It's also a quiet admission that mega-fund biotech investing didn't produce proportionate returns, hence the move to smaller, more concentrated bets. Worth reading for anyone raising in AI-bio: the data strategy pitch just got harder to sell to this class of investor.
The capital is moving. Physical AI went from a niche to a measurable slice of venture allocation in one year. For builders: if you're in robotics or autonomous systems, this is validation that the bottleneck was capital, not capability. For investors: the returns from pure software foundation models are compressing fast enough that LPs are redirecting into embodied AI, which still has asymmetric upside.
The interesting claim here isn't that IPOs return cash to LPs, everyone knows that. It's the concentration mechanism: big-name funds with existing LP relationships raise faster off that liquidity, smaller funds don't, and the gap compounds. For emerging managers, this is a warning to lock in LP commitments before the AI IPO wave crests, not after.
Menlo's proximity to Anthropic gives Murphy a genuinely informed vantage point on where model-layer economics are heading, and $3 billion deployed signals VCs are still willing to write large single-sector checks despite valuation concerns. Worth reading for the
The doubling year over year and the concentration in mega-rounds confirms what everyone already suspects: capital is piling almost exclusively into a small number of AI infrastructure and frontier lab bets rather than spreading across the broader startup market. For founders outside that tier, this is a warning that the bar for raising is bifurcating hard, either you're in the AI infrastructure story or you're competing for a shrinking pool of everything else. For investors, watch for the correction risk building in that concentration.